A prescribing assessment should establish both that dapoxetine addresses the patient's problem and that its use is medically suitable. Asking only how long intercourse lasts cannot settle those questions. Important findings may lead to a different treatment, further assessment or no Priligy prescription.

The consultation should be clear and respectful. Accurate answers help identify the treatment target and avoid preventable harm; they are not hurdles to overcome to obtain a preferred tablet.

Establish the problem before screening for the medicine

The history should cover onset, consistency, approximate ejaculation timing, perceived control and the impact on wellbeing or relationships. It should also distinguish erection loss, painful ejaculation and other sexual concerns.

Newly acquired early ejaculation may need assessment for contributing conditions. A symptom that began after a medicine change or alongside pelvic symptoms deserves that context. Diagnosing PE and establishing eligibility for a particular product are related but separate decisions.

Clinical examination and targeted investigations follow the history. Broad laboratory testing is not automatically needed for every PE concern, while a relevant finding should not be ignored merely because an online questionnaire did not ask about it.

What the safety review should cover

Information to discloseWhy it matters for Priligy assessment
Any previous loss of consciousnessA history of syncope is a contraindication in the cited label
Dizziness or near-fainting when standingRelevant to orthostatic tolerance and the pre-treatment standing assessment
Diagnosed heart conditionsSpecified significant cardiac diseases can rule out treatment
Liver or kidney impairmentSeverity can change eligibility or require caution
Mania, significant depression or other psychiatric historyMay affect suitability and coordinated treatment decisions
Seizures or epilepsyRequires a condition-specific review
All medicines and substances usedContraindications and interactions extend beyond daily prescriptions

This table is not an exhaustive self-clearance checklist. A clinician needs to interpret the actual diagnosis and history rather than accept a patient's guess that a condition is "mild enough."

Why a seated blood-pressure reading is not the whole test

The product information calls for an orthostatic assessment before treatment, including blood pressure and pulse measured lying down and standing. The purpose is to assess the response to posture change, not simply to obtain one reassuring number.

Mention episodes related to standing, heat, a blood draw or another trigger. A blackout years ago can still matter. Do not omit it because it seemed understandable at the time or because there has not been a recent recurrence.

If documented or suspected orthostatic reactions are present, the treatment decision changes. Advice to drink water cannot replace the assessment or make an unsuitable finding irrelevant.

Reconcile the actual medicines, not just broad categories

The clinician or pharmacist needs drug names, strengths and schedules. Include occasional migraine treatments, pain medicines, antibiotics, sleep medicines, herbal preparations and recently stopped treatments.

Antidepressants and other serotonergic products are especially important, but the review is not limited to them. Drugs affecting dapoxetine metabolism, treatments influencing blood pressure and erection medicines can also matter. The cited Irish information advises against use with PDE5 inhibitors.

If you use a combined sexual-function tablet, bring the packaging or dispensing record. Do not assume that a familiar brand contains only the ingredient you intended to buy. An unidentified product creates an information gap that should be resolved before another prescription is added.

The consultation should end with usable instructions

A patient should understand the selected dose, advance-use timing, maximum frequency, administration directions and relevant alcohol precautions. Counseling should explain symptoms suggesting fainting and how to avoid injury if they occur.

Also clarify the review plan. Know how to contact the service after a concerning reaction or before taking a new interacting medicine. An automatic renewal without a way to discuss those changes is not a complete treatment plan.

Ask the prescriber:

  • What diagnosis is being treated, and what improvement should I assess?
  • Which part of my history most affects suitability?
  • What symptoms mean I should seek advice before another dose?
  • What should I do if a new medicine is prescribed elsewhere?
  • When and how will benefit and tolerability be reviewed?

If a remote consultation cannot resolve a required examination or an uncertain history, further assessment may be needed. The appropriate outcome is a medically coherent decision, not merely a completed form and a supply of tablets.